Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KF6X
|
|||
| Former ID |
DCL000884
|
|||
| Drug Name |
MLN3897
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 2 | [1] | |
| Company |
Millenium Pharmacenticals; Sanofi Aventis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 1 (CCR1) | Target Info | Antagonist | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.